Manifestaciones cardiológicas de la infección por SARS-COV-2
DOI:
https://doi.org/10.66737/ier.zub.279Keywords:
COVID-19, cardiovascular system, myocardial damageAbstract
SARS-CoV-2 infection, which origin the clinical syndrome known as COVID19, presents the respiratory system affection, in form of pneumonia and respiratory insufficiency, as its main clinical manifestation. However, SARS CoV2 infection can interact with other systems such as the cardiovascular system. This interaction can manifest in many ways, infecting the cardiovascular system or modifying the standard treatment of common cardiovascular diseases. This article focusses on reviewing the mechanisms, consequences, and management of cardiovascular manifestations of SARSCoV-2, as well as the main consequences in the standard management of
cardiovascular pathologies.
Downloads
References
Álvarez-Garcia J, Lee S, Gupta A, Cagliostro M, Joshi AA, Rivas-Lasarte M, et al., (2020). Prognostic impact of prior heart failure in patients hospitalized with COVID-19. En: Journal American College of cardiology;76:2334-48.
Akhmerov A, Marbán E. COVID-19 and the Heart (2020). En: Circulation Reserch; 126:1443-55.
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al., COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up (2020). En Journal American College of Cardiology; 75:2950-73.
Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al., COVID-19 and cardiovascular disease (2020). En: Circulation; 141:1648-55. Fulchand S. Covid-19 and cardiovascular disease (2020). En: British Medical Journal; 369:m1997.
García-Fernández MA, Azcaráte-Agüero PM, Cabrera-Schulmeyer MC, Pozo Leon JL, Gómez de Diefo JJ. Actualización de las recomendaciones sobre la logística de uso de la ecocardiografía durante la pandemia de COVID-19. Recomendaciones de la Sociedad Española de Imagen Cardíaca (2020). En: Revista de Ecocardiografía Práctica (RETIC); 3:1-5.
Geng YJ, Wei ZY, Qian H-Y, Huang J, Lodato R, Castriotta RJ. Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019 (2020). En: Cardiovascular Pathology; 47:107228.
Gubitosa JC, Kakar P, Gerula C, Nossa H, Finkel D, Wong K, , et al., Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review (2020). En: Journal American College of Cardiology Case Report; 2:2260-4.
Ibáñez B. Myocardial infarction in times of COVID-19 (2020). En: Revista Española de Cardiología; 73: 975–7.
Imazio M, Klingel K, Kindermann I, Brucato A, De Rosa FG, Adler Y, et al., COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis? (2020). En: Heart;106:1127-31.
Jabri A, Kalra A, Kumar A, Alameh A, Adroja S, Bashir H, et al., Incidence of stress cardiomyopathy during the Coronavirus Disease 2019 pandemic (2020). En: Journal of the American Medical Association Open; 3:e2014780.
Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, et al., Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance (2021). En: European Heart Journal:ehab075.
Peng Y, Meng K, He M, Zhu R, Guan H, Ke Z, et al., Clinical characteristics, and prognosis of 244 cardiovascular patients suffering from Coronavirus disease in Wuhan, China (2020). En: Journal of American Heart Association;9:e016796.
Rudski L, Januzzi JL, Rigolin VH, Bohula EA, Blankstein R, Patel AR, et al., Multimodality imaging in evaluation of cardiovascular complications in patients with COVID-19: JACC Scientific Expert Panel (2020). En: Journal American College of Cardiology; 76:1345–57.
Romaguera R, Ribera A, Güell-Viaplana F, Tomás-Querol C, Muñoz-Camacho JF, Agudelo V. Reducción de los ingresos por infarto agudo de miocardio con elevación del segmento ST en Cataluña durante la pandemia de COVID- 19 (2020). En: Revista Española de Cardiología; 73:778-80.
Sandoval Y, Januzzi JL Jr, Jaffe AS. Cardiac troponin for assessment of myocardial injury in COVID-19: JACC Review Topic of the Week (2020). En: Journal American College of Cardiology; 76:1244-58.
Soeiro AM, Leal TCAT, Pereira MP, Lima EG, Figueiredo ACBDS, Petriz JLF, Precoma DB, Serrano CV Jr. Position statement on the use of antiplatelet agents and anticoagulants in patients infected with the new Coronavirus (COVID-19) – (2020). En: Arquivos Brasileiros de Cardiologia; 115:292-301.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al., Fourth Universal definition of myocardial infarction (2018). En: Journal American College of Cardiology;72:2231-64.
Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications (2020). En: European Heart Journal ; 41:1798–800.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Juan Lizandro Rodríguez Hernández, Alejandro Gutiérrez Fernández, Guillermo Pinillos Francia, José Eduardo Ramírez Batista, Jonathan Calavia Arriazu, María Pilar Portero Pérez, Pedro María Azcarate, Luis Javier Alonso Pérez, Javier Ibero Valencia (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Los autores que publican en Zubía conservan los derechos de autor de sus trabajos y autorizan a la revista la primera publicación de los mismos.
Los artículos se publican bajo la licencia Creative Commons Atribución–No Comercial–Compartir Igual (CC BY-NC-SA), que permite su uso, distribución y reproducción en cualquier medio, siempre que se cite adecuadamente la autoría original, no se realice un uso comercial y se mantenga la misma licencia.
